

Expression of NS3/NS4A Proteins of Hepatitis C Virus in Huh7 Cells Following Engineering Its Eukaryotic Expression Vector

Mohammad Amin Behzadi,^{1,2} Abdolvahab Alborzi,¹ Gholamreza Pouladfar,¹ Mehdi Dianatpour,^{3,4} and Mazyar Ziyaeyan^{1,*}

¹Professor Alborzi Clinical Microbiology Research Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, IR Iran

²Student Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran

³Stem Cell and Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran

⁴Department of Medical Genetics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran

*Corresponding author: Mazyar Ziyaeyan, Professor Alborzi Clinical Microbiology Research Center, Namazi Hospital, Shiraz University of Medical Sciences, P. O. Box: 7193711351, Shiraz, IR Iran. Tel: +98-7136474304, Fax: +98-7136474303, E-mail: ziyaeyanm@sums.ac.ir

Received 2015 January 26; Revised 2015 May 21; Accepted 2015 June 8.

Abstract

Background: Although the development of novel therapeutic regimens to combat hepatitis C virus (HCV) infection have been speeded up with successful results, no efficient vaccines exist yet.

Objectives: This study aimed to construct a eukaryotic expression vector encoding nonstructural proteins, NS3/NS4A, of HCV genotype 3a, and evaluate its expression on Huh7 cell surface.

Materials and Methods: The NS3/NS4A sequence was isolated from a patient with HCV-3a chronic infection, cloned into intermediate vector pTZ57R/T, and then used for engineering a mammalian expression vector, pDisplay, to direct the respective protein to the secretory pathway and anchor it to the plasma membrane. The expression of the protein in Huh7 cell, which was transiently transfected with the vector using Lipofectamine, was determined by immunocytochemical staining assay with fluorescein isothiocyanate (FITC)-conjugated antibodies to the HA/myc tags located besides the fusion fragment.

Results: The results showed that the fragment was successfully amplified and cloned into a eukaryotic expression vector. Sequencing and enzyme digestion analysis confirmed the cloned gene completion and its correct position in the pDisplay-NS3/NS4A plasmid. Immunocytochemical staining revealed that the target protein was expressed as a membrane-anchored protein in the Huh7 cells.

Conclusions: This study can serve as a fundamental experiment for the construction of a NS3/NS4A eukaryotic expression vector and its expression in mammalian cells. Further research is underway to evaluate the fragment immunogenicity in lab animal models.

Keywords: Hepatitis C Virus, NS3, NS4A, Expression

1. Background

Nowadays, hepatitis C virus (HCV) infection represents a major public health concern, affecting over 170 million individuals worldwide (1, 2). Infected patients may be at risk of progressive liver fibrosis and cirrhosis and hepatocellular carcinoma (HCC), as well as life-threatening and irreversible extrahepatic injuries, even after transplantation and treatment (3-5).

Although novel therapeutic regimens to combat HCV infection have been developed which can cure a large proportion of chronically infected patients (2), important concerns related to HCV infection control still exist. First, therapy in infected patients with HCV genotype 3, known as the second most prevalent and the most-difficult-to-treat type, resulted in the lower rate of sustained virological response (SVR), compared with other genotypes (6, 7). Secondly, the poor compliance to the treatment protocols due the high cost and relatively long period of treatment may result in the most patients'

refusal to accurately follow up or even accept the treatment protocols (8, 9). Therefore, it is estimated that the infected population will increase further in the next few years (10). Consequently, using treatment as an effective control strategy could not completely interrupt the transmission and decrease the disease burden; so, more attempts to develop other low-cost but efficient HCV preventive strategies such as vaccines are needed.

Hepatitis C virus belongs to the *Flaviviridae* family with a positive-sense RNA genome which encodes different structural and non-structural proteins (11). It was shown that high levels of viral genome mutation lead to heterogeneity (12), as well as some modifications in virus regulatory elements (13). Moreover, the creation of new subtypes among different genotypes of the virus is also highly possible (14). Therefore, the development of HCV universal vaccine is faced with major challenges and no vaccine still exists (15).

To date, DNA vaccines as the safest and most promising means are designed or under clinical trials to elicit host immune responses (humoral and cellular) against HCV, as well as HIV and Influenza (16). Previous study confirmed HCV-specific immunogenicity following vaccination with a DNA vaccine candidate harboring immunodominant Core, E2, NS3 and NS5B HCV epitopes in BALB/c mice (17). It was revealed that the antigenic epitopes of the target proteins expressed by DNA vaccine plasmids more closely resembled the native viral proteins than those of traditional vaccines such as the attenuated and subunit ones (16). Hepatitis C virus DNA vaccination has been useful for prevention or even as a therapeutic way to control such infections by activating T-helper and cytotoxic T cells, as well as antibody responses in animal models (16), but genotype 1 of the virus has been more studied. Limited research has been carried out on designing DNA vaccines for genotype 3.

2. Objectives

Paving way to develop a novel DNA vaccine candidate for HCV genotype 3a, the current study aimed to construct a eukaryotic expression vector encoding NS3/NS4A nonstructural proteins of the respective genotype and evaluate its expression in Huh7 cell line.

3. Materials and Methods

3.1. Construction and Identification of Recombinant Plasmid

A set of primers were designed according to the 14 available NS3/NS4A nucleotide sequence data of 3a subtype of HCV from the GenBank database of the National Center for Biotechnology Information (NCBI). The sequences were initially analyzed by Lasergene sequence analysis software package (DNASTar, Madison, WI, USA); the consensus sequence for NS3/NS4A was generated using Clustal X (version 1.8) software and the primer set was designed based on the result (forward NS3/4A: 5'-AGATCTGCCCCGATCA-CAGCATACGCCC-3'; reverse NS3/4A: 5'-CCGCGGGCACTCTC-CATCTCATCG -3' caring, respectively, the BglII and SacII cloning sites (underlined and boldface)). Viral RNA was extracted using commercially available kit (Invitex, Berlin, Germany) from 200 µL plasma of a patient infected with HCV genotype 3a, confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR) and nested PCR, according to the method of Ohno et al. (18). The extracted RNA was used for cDNA synthesis using cloned avian myeloblastosis virus (AMV) reverse transcriptase (Invitrogen, Carlsbad, CA, USA) and PCR was performed using Platinum® Taq DNA polymerase high fidelity (Invitrogen, Carlsbad, CA, USA) in a 25 µL reaction. The amplified NS3/NS4A fragment was cloned into pTZ57R/T intermediate cloning vector (Fermentas, Lithuania) and transformed into *Escherichia coli* DH5α competent cells (TaKaRa Biotechnology Co., Dalian, China).

The respective recombinant plasmid was extracted and

cleaved by BglII and SacII (Fermentas, Lithuania) and inserted into the similarly digested eukaryotic expression vector pDisplay (Invitrogen, Carlsbad, CA, USA) with T4 DNA ligase (Invitrogen, Carlsbad, CA, USA) and transformed into *E. coli* DH5α. The pDisplay vector contains hemagglutinin A (HA) epitope tag in upstream and myc epitope in downstream of the cut sites which allow for the detection of the expressed recombinant proteins by immunofluorescence assay using anti-HA/myc antibodies. PCR and restriction endonuclease assays and sequencing in ABI 3130 Genetic Analyzer by Big-Dye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, USA) were used to screen, identify, and confirm positive clones in both cloning steps. The resulted recombinant plasmid was named pDisplay-NS3/NS4A.

3.2. Cell Transfection

The Huh7 cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Germany) containing 10% fetal bovine serum (Gibco, Germany) at 37°C and 5% CO₂. The logarithmic phase of the cells was harvested and seeded into six-well culture plates (2 × 10⁵ cells/well) with 2 mL of the plating medium to become 70% - 80% confluent. The cells were transiently transfected with 4.0 µg purified pDisplay-NS3/NS4A plasmid, using 10 µL Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions.

3.3. Immunocytochemical Staining

After 48 hours of transfection, the cells were permeabilized and the expression of the proteins was determined using mouse monoclonal antibody to the C-terminal HA tag and goat polyclonal antibody to N-terminal myc tag of the fusion construct, according to the manufacturer's guideline (Abcam, UK). The expression of the fusion proteins were evaluated under fluorescence microscope. The nontransfected cells were considered as blank, while empty pDisplay-transfected cells were considered as negative control (mock) and both were stained with anti-HA and -myc FITC-conjugated antibodies. The sequences of the HA/myc tags in the empty pDisplay vector are not in-frame for expression, distinctly. They can only be expressed if their genes are completed with the in-frame inserted sequence containing the sticky ends of the recommended restriction enzymes. Membrane fluorescence was detected using Zeiss Axioskop 2 fluorescence microscope (Zeiss, Göttingen, Germany).

4. Results

4.1. Evaluation of the Reverse-Transcriptase Polymerase Chain Reaction Product and Recombinant pDisplay-NS3/NS4A Eukaryotic Expression Vector


RT-PCR amplified the NS3/NS4A fragment and the products were loaded on 1.5% agarose gels; the band for full-

length of the respective cDNA was 2055 bp (Figure 1A). The fragment was successfully cloned into the intermediate cloning vector (Figure 1B) and then into pDisplay eukaryotic expression vector (5325 bp, Figure 1C). The fragment was confirmed by BglII and SacII digestion and electrophoresis. Besides, the obtained DNA sequencing results confirmed the cloned gene completion, correct position (Figure 2), and the analysis revealed its high homology with the sequences of NS3/NS4A of HCV genotype 3a database in GenBank (Figure 3).

4.2. Evaluation of Protein Expression of pDisplay-NS3/NS4A in Huh7 Cells

After transfection, the expression of pDisplay-NS3/NS4A was analyzed by immunocytochemical staining. The results of immunofluorescent assay using antibodies to hemagglutinin A tag indicated that the respective protein was being successfully expressed on the surface of the Huh7 cells, when compared with the control group. The result of the assay using antibodies to myc tag was the same (Figure 4).

Figure 1. Polymerase Chain Reaction and Restriction Enzyme Analysis



A: PCR amplification of NS3/NS4A using specific primers, 1 kb DNA ladder (Vivantis, Malaysia). B: recombinant T/A cloning vector digested by BglII and SacII enzymes, showing the 2055 bp insert, 1 kb DNA ladder (Fermentas, Lithuania). C: pDisplay-NS3/NS4A plasmid digested by BglII and SacII enzymes, showing the 2055 bp insert, 1 kb DNA ladder (Fermentas, Lithuania).




Figure 2. Plasmid Map of pDisplay-NS3/NS4A and the Amino Acid Sequence of the Fragment





Figure 3. Phylogenetic Analysis of the Studied NS3/NS4A Sequence in Comparison With 14 NS3/NS4A Sequence Data of Hepatitis C Virus Genotype 3a

Figure 4. Fluorescence Microscopy of Huh7 Cells 48 Post Transfection With pDisplay-NS3/NS4A After Staining With Fluorescein Isothiocyanate Conjugated Antibodies to the HA/myc Tags



A: no immunofluorescence was detected in mock-infected Huh7 cells using conjugated antibodies to the HA tag. B: HA expression and its specific localization (arrows) at the cell surface membrane of the Huh7 cells. C: no immunofluorescence was detected in mock-infected Huh7 cells using conjugated antibodies to the myc tag. D: myc expression and its specific localization (arrows) at the cell surface membrane of the Huh7 cells.

5. Discussion

Recently, the utilization of the nonstructural genes as a DNA vaccine has revealed quite promising results in lab animal models (19) and also in clinical trials (20). Previous studies demonstrated that the resolution of acute infection was closely associated with the specific T cell responses to different HCV proteins (21, 22). The comparison of the peripheral blood mononuclear cell responses to the recombinant HCV proteins core, NS3, NS4, and NS5 among the patients who spontaneously clear the virus showed that the correlation was remarkably high with responses to NS3 (22). Although this protein is able to down-regulate the innate immune responses by various pathways such as decreasing the expression of interferon stimulatory genes (ISGs) (23), owing to its multiple important epitopes with the ability to induce potent immune responses, it has been recognized as one of the central targets of interest for new vaccine developments (17, 24). A study by Lang et al. in both mice and Rhesus macaques demonstrated strong HCV NS3-and NS4A-specific cellular immune responses preceded by the injection of DNA vaccine encoding the respective proteins (19). Therefore, it seems that nonstructural proteins play an important role in developing possible future HCV DNA vaccines. In the present study, the NS3/NS4A fragment of the nonstructural genome of the virus was applied in the construction of our eukaryotic expression vector.

Most of the previous HCV DNA vaccine studies were mainly focused on genotype 1 of the virus (25, 26) and to our knowledge limited research has been performed on genotype 3. A recent study on the global determination of HCV major genotypes distribution reported that HCV genotype 1 was the most prevalent worldwide (46.2%), followed by genotype 3 (30.1%) (27). Similarly, in Iran, it was shown that genotypes 1 and then 3 were the most prevalent HCV genotypes among both nontransplant (28) and transplant patients (29). Hence, in the present study, the nonstructural proteins of genotype 3a of the virus were investigated. The reason of utilizing NS4A protein as a fusion peptide combined with the NS3 protein in our study was its reported roles in the enhancement of stability, expression, and immunogenicity of the NS3 protein. It was revealed that in the absence of NS4A, the full-length NS3 protein will be diffusely distributed in the cytoplasm and nucleus and rapidly degraded (30). The very hydrophobic amino-terminal domain of NS4A assists in the NS3-NS4A complex anchoring and localization in the membrane and may protect it against proteolytic attack (31). Therefore, co-expression of NS4A will improve the survival of NS3 and its stability in cellular context, and consequently the immunogenicity of the respective protein (32). Although the rationale behind the observation in increasing of NS3 expression in the presence of NS4A was not determined (32); it may be related to lower degradation rate of the NS3 protein after co-expression with NS4A.

Selection and designing the DNA vaccine vectors play an important role in increasing the efficiency of vaccination (33). Numerous kinds of eukaryotic expression vectors have been widely applied in this system. We used pDisplay as a eukaryotic expression vector in this study, due to some of its documented benefits including: (i) the vector is under the control of the human cytomegalovirus (CMV) immediate-early promoter/enhancer which helps to increase the expression level of the recombinant protein (34); (ii) the HA and myc epitopes on both sides of the expressed recombinant proteins allow the detection of the fusion peptide with anti-HA/myc antibodies; (iii) the murine Ig k chain leader sequence and platelet-derived growth factor receptor transmembrane domain (PDGFR-TM), located at the N-terminus and the C-terminus, respectively, which direct the fusion protein to the secretory pathway and anchor it to the plasma membrane (35). In the present study, the results of the immunofluorescent assay confirmed that the target protein anchored to the Huh7 cell membrane. Previous studies on immunization against other pathogens with DNA vaccines revealed that the antigenic peptide produced on the cell surface was thought to be more immunogenic than those secreted or expressed as intracellular forms (36, 37). This may be resulted from the higher chance of antigen capturing and processing by antigen presenting cells (38). In most of the earlier studies on HCV DNA vaccines, the target proteins were expressed within the cell, not on the cell surface (39, 40).

Considering the future aim to test and develop a DNA vaccine candidate against HCV genotype 3a, we designed, constructed and evaluated the in vitro expression of a eukaryotic expression vector, coding NS3/NS4A proteins of the virus. In this fundamental experiment, the target fragment of HCV genotype 3a was successfully reverse transcribed, amplified, cloned into a eukaryotic expression vector, and expressed in Huh7 mammalian cells. Further research is underway to evaluate this fragment immunogenicity in lab animal models.

Acknowledgments

Our special thanks are to Dr. Hassan Khajehei for his copy editing of the manuscript.

Footnotes

Authors' Contribution: This study was based on the idea of Mohammad Amin Behzadi and Maziar Ziyaeyan. Maziar Ziyaeyan and Abdolvahab Alborzi supervised the project. All the authors contributed to the conception of the work, design of the study, drafting and revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work.

Funding/Support: This research was a Ph.D. thesis No. 93-7033, financially supported by Shiraz university of medical sciences and Professor Alborzi clinical microbiology research center.

References

1. Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, et al. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. *J Viral Hepat.* 2015;**22**(2):175–83. doi: 10.1111/jvh.12278. [PubMed: 25040391]
2. Shiffman ML, Benhamou Y. Cure of HCV related liver disease. *Liver Int.* 2015;**35**(Suppl 1):71–7. doi: 10.1111/liv.12734. [PubMed: 25529090]
3. Salomon JA, Weinstein MC, Hammit JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. *JAMA.* 2003;**290**(2):228–37. [PubMed: 12851278]
4. Sarvari J, Norozian H, Fattahi MR, Pirbonyeh N, Moattari A. The Role of Interferon Gamma Gene Polymorphism (+874A/T, +2109A/G, and -183G/T) in Response to Treatment Among Hepatitis C Infected Patients in Fars Province, Southern Iran. *Hepat Mon.* 2014;**14**(1):e14476. doi: 10.5812/hepatmon.14476. [PubMed: 24497880]
5. Behzadi MA, Ziyaeyan M. Hepatitis C Virus Load in Seropositive Liver and Kidney Transplant Recipients by Quantitative Real-Time PCR Before and After Transplantation. *Jundishapur J Microbiol.* 2013;**6**(8) doi: 10.5812/jjm.7365.
6. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. *N Engl J Med.* 2013;**368**(20):1867–77. doi: 10.1056/NEJMoa1214854. [PubMed: 23607593]
7. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. *N Engl J Med.* 2014;**370**(21):1993–2001. doi: 10.1056/NEJMoa1316145. [PubMed: 24795201]
8. Innes H, Goldberg D, Dillon J, Hutchinson SJ. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most? *Gut.* 2015;1800–9. doi: 10.1136/gutjnl-2014-308166. [PubMed: 25378522]
9. Backx M, Lewszuk A, White JR, Cole J, Sreedharan A, van Sanden S, et al. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. *J Viral Hepat.* 2014;**21**(3):208–15. doi: 10.1111/jvh.12132. [PubMed: 24438682]
10. Hill A, Cooke G. Medicine. Hepatitis C can be cured globally, but at what cost? *Science.* 2014;**345**(6193):141–2. doi: 10.1126/science.1257737. [PubMed: 25013048]
11. Lohmann V, Koch JO, Bartenschlager R. Processing pathways of the hepatitis C virus proteins. *J Hepatol.* 1995;**24**(2 Suppl):11–9. [PubMed: 8836884]
12. Omran MH, Nabil W, Youssef SS, El-Sayed M, El Awady MK. Heterogeneity and New Epitopes of Hepatitis C Virus Genotype 4. *Hepat Mon.* 2013;**13**(8) doi: 10.5812/hepatmon.10521. [PubMed: 2413059]
13. Anjum S, Ali S, Ahmad T, Afzal MS, Waheed Y, Shafi T, et al. Sequence and Structural Analysis of 3' Untranslated Region of Hepatitis C Virus, Genotype 3a, From Pakistani Isolates. *Hepat Mon.* 2013;**13**(5). doi: 10.5812/hepatmon.8390.
14. Moghadam FS, Mohebbi SR, Hosseini SM, Damavand B, Zali MR. A new subtype of hepatitis C virus genotype 3: Analysis of available evidence. *Hepat Mon.* 2013;**13**(8). doi: 10.5812/hepatmon.13380.
15. Echeverria N, Moratorio G, Cristina J, Moreno P. Hepatitis C virus genetic variability and evolution. *World J Hepatol.* 2015;**7**(6):831–45. doi: 10.4254/wjh.v7.i6.831. [PubMed: 25937861]
16. Smith HA. Regulation and review of DNA vaccine products. *Dev Biol.* 1999;**104**:57–62. [PubMed: 11713825]
17. Sabet LP, Taheri T, Memarnejadian A, Azad TM, Asgari F, Rahimnia R, et al. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. *Hepat Mon.* 2014;**14**(10) [PubMed: 11713825]
18. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. *J Clin Microbiol.* 1997;**35**(1):201–7. [PubMed: 8968908]
19. Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. *Vaccine.* 2008;**26**(49):6225–31. doi: 10.1016/j.vaccine.2008.07.052. [PubMed: 18692108]
20. Weiland O, Ahlen G, Diepolder H, Jung MC, Levander S, Fons M, et al. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. *Mol Ther.* 2013;**21**(9):1796–805. doi: 10.1038/mt.2013.119. [PubMed: 23752314]
21. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. *J Clin Invest.* 1996;**98**(3):706–14. [PubMed: 8698862]
22. Diepolder HM, Zachoval R, Hoffmann RM, Jung MC, Pape GR, Wierenga EA, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. *Lancet.* 1995;**346**(8981):1006–7. [PubMed: 7475549]
23. Khanlari Z, Sabahi F, Hosseini SY, Ghaderi M. HCV NS3 Blocking Effect on IFN Induced ISGs Like Viperin and IL28 With and Without NS4A. *Hepat Mon.* 2014;**14**(4). doi: 10.5812/hepatmon.17822. [PubMed: 24976840]
24. Hosseini SY, Sabahi F, Moazzeni SM, Modarressi MH, Saberi Firoozi M, Ravanshad M. Construction and Preparation of Three Recombinant Adenoviruses Expressing Truncated NS3 and Core Genes of Hepatitis C Virus for Vaccine Purposes. *Hepat Mon.* 2012;**12**(9). doi: 10.5812/hepatmon.6130. [PubMed: 23087750]
25. Ullah S, Shah MA, Riaz N. Recent Advances in Development of DNA Vaccines Against Hepatitis C virus. *Indian J Virol.* 2012;**23**(3):253–60. doi: 10.1007/s13337-012-0058-3. [PubMed: 24293811]
26. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. *J Hepatol.* 2011;**54**(6):1273–85. doi: 10.1016/j.jhep.2010.09.040. [PubMed: 21236312]
27. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology.* 2015;**61**(1):77–87. doi: 10.1002/hep.27259. [PubMed: 25069599]
28. Sefidi FJ, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. *Hepat Mon.* 2013;**13**(1):e7991. doi: 10.5812/hepatmon.7991.
29. Feyznehzad R, Behzadi MA, Yaghobi R, Ziyaeyan M. Determining major genotypes of hepatitis C virus among transplant recipients by real-time polymerase chain reaction assay. *Jundishapur J Microbiol.* 2015;**8**(2):e16722. doi: 10.5812/jjm.16722. [PubMed: 25793097]
30. Wolk B, Sansonno D, Krausslich HG, Dammacco F, Rice CM, Blum HE, et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. *J Virol.* 2000;**74**(5):2293–304. [PubMed: 10666260]
31. Tanji Y, Hijikata M, Satoh S, Kaneko T, Shimotohno K. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. *J Virol.* 1995;**69**(3):1575–81. [PubMed: 7853491]
32. Frelin L, Alheim M, Chen A, Söderholm J, Rozell B, Barnfield C, et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. *Gene Ther.* 2003;**10**(8):686–99. [PubMed: 12692597]
33. Williams JA. Vector Design for Improved DNA Vaccine Efficacy, Safety and Production. *Vaccines (Basel).* 2013;**1**(3):225–49. doi: 10.3390/vaccines1030225. [PubMed: 26344110]
34. Hasan UA, Abai AM, Harper DR, Wren BW, Morrow WJW. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. *J Immun Methods.* 1999;**229**(1):1–22. doi: 10.1016/S0022-1759(99)00104-0.
35. Yang J, Zhang Z, Lin J, Lu J, Liu B, Zeng S, et al. Detection of MMP activity in living cells by a genetically encoded surface-displayed FRET sensor. *Biochimica et Biophysica Acta.* 2007;**1773**(3):400–7. doi: 10.1016/j.bbamcr.2006.11.002. [PubMed: 17187878]
36. Puttikhant C, Kasinrerak W, Srisa-ad S, Duangchinda T, Silakate W, Moonsom S, et al. Production of anti-dengue NS1 monoclonal antibodies by DNA immunization. *J Virol Methods.* 2003;**109**(1):55–61.

- [PubMed: 12668268]
37. Haddad D, Liljeqvist S, Kumar S, Hansson M, Ståhl S, Perlmann H, et al. Surface display compared to periplasmic expression of a malarial antigen in *Salmonella typhimurium* and its implications for immunogenicity. *FEMS Immunol Med Microbiol.* 1995;**12**(3-4):175-86. [PubMed: 8745001]
38. Fornis X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. *Vaccine.* 1999;**17**(15):1992-2002. [PubMed: 10217599]
39. Alvarez-Lajonchere L, Duenas-Carrera S. Advances in DNA immunization against hepatitis C virus infection. *Hum Vaccin.* 2009;**5**(8):568-71. [PubMed: 19736511]
40. Ullah S, Shah MAA, Riaz N. Recent advances in development of DNA vaccines against hepatitis C virus. *Indian J Virol.* 2012;**23**(3):253-60. [PubMed: 24293811]

Archive of SID